Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:2/2/2009

SAN FRANCISCO, Feb. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

  • The 11th Annual BIO CEO and Investor Conference on Monday, February 9, at 9:30 a.m. Eastern Time at the Waldorf Astoria Hotel in New York
  • The ROTH Capital Partners' 21st Annual OC Growth Stock Conference on Tuesday, February 17, at 3:00 p.m. Pacific Time at the Ritz Carlton Hotel in Dana Point, California

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... Standard ... 75, an annual ranking and recognition of the largest closely held companies headquartered ... ranked from 2008-2016. In addition, Standard Process was awarded the Talent Award for ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... 30, 2016 , ... The Cronovo Smartwatch, the first on ... consumers at an affordable price, is now available on the crowdfunding website ... game changer” when it comes to the smartwatch. , "With Cronovo, we’ve combined ...
(Date:11/30/2016)... ... 2016 , ... The Valley’s leading orthopedic practice, OrthoArizona - ... North Phoenix and Chandler locations. , The new North Phoenix location is located ... 3rd St, Suite 300 in Phoenix. The practice’s new Chandler location is conveniently ...
(Date:11/30/2016)... ... November 30, 2016 , ... BrightStar Care of Wellington , a ... was recently named the 2016 Provider and Employer of Choice by Home Care Pulse. ... scores, and only providers with the highest quality receive the Best of Home Care ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
(Date:12/2/2016)... In the first ever attempt to include ... from C. sativa, the Hebrew University in Jerusalem, the ... II , the Universita` del Piemonte Orientale and Phytoplant ... and unified inventory of phytocannabinoids of different botanical origin. ... remarkable chemical and structural diversity of phytocannabinoids. As a ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and ... financial guidance for 2017 and provide updated financial guidance ... also conduct a conference call on that day with ... company,s financial guidance. The conference call will ... general public can access a live webcast of the ...
Breaking Medicine Technology: